BioLineRx to Present Successful Results of Phase 1/2 Study for BL-7010
News Jun 19, 2015
BioLineRx Ltd. has announced that it will present positive safety results of its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease, at the 16th International Celiac Disease Symposium (ICDS 2015), to take place from June 21-24 in Prague, Czech Republic. The Phase 1/2 results were previously announced in November 2014.
Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients, on Wednesday, June 24, in the Novel Treatments session.
BL-7010 was found to be safe and well tolerated in the single-dose phase, and the optimal safe dose for future development was determined in the repeated-dose phase.
The Company is in the final stages of additional non-clinical studies and formulation development for BL-7010 in preparation for the upcoming randomized, placebo-controlled efficacy study, which is expected to commence in the fourth quarter of 2015.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE